Introduction {#s1}
============

Osteoarthritis (OA) is the most common degenerative joint disorder worldwide ([@B22]). Osteoarthritis could cause pain and disability in elderly people ([@B23]; [@B41]). It is considered that OA is caused by the combination of risk factors with increasing age and obesity ([@B23]; [@B22]). Osteoarthritis is a complex disease and has a strong genetic component ([@B41]). To identify more genetic signals, genome-wide association study (GWAS) has been widely used and elucidated some OA susceptibility genes ([@B41]; [@B31]; [@B30]; [@B42]; [@B32]). However, these susceptibility genes could explain only a small part of heritability of OA ([@B41]; [@B31]; [@B30]; [@B42]; [@B32]). It is suggested that the identification of disease-related pathways may contribute to understand the genomic etiology of OA ([@B3]).

In recent years, kinds of bioinformatics software and databases have been developed, especially for the identification of disease-related pathways such as VEGAS (Versatile Gene-based Association Study) ([@B18]), INRICH (INterval enRICHment analysis) ([@B13]), and GSA-SNP2 ([@B39]). Meanwhile, these methods have been widely used in OA-related disease rheumatoid arthritis (RA) ([@B6]; [@B5]; [@B14]; [@B28]; [@B43]), but not in OA. Here, we first selected all significant OA risk variants identified by GWAS and evaluated their distribution in genome coding and noncoding regions. Second, we then conducted an expression quantitative trait loci (eQTLs) analysis to evaluate the effect of these genetic variants on gene expression. Third, we performed a pathway analysis of OA susceptibility genes detected by OA-related genetic pathways. Finally, we conducted an OA case--control gene expression analysis to evaluate the differential expression of these OA risk genes.

Materials and Methods {#s2}
=====================

Selection of OA Risk Variants {#s2_1}
-----------------------------

We selected the potential OA risk variants identified by GWAS by searching for the NHGRI GWAS catalog database using the keyword "osteoarthritis" ([@B37]; [@B21]; [@B2]). Finally, we selected 187 genetic variants associated with OA (*P* \< 1.00E−05) ([@B37]; [@B21]; [@B2]). These variants are associated with OA, OA of the hip, OA of the knee, or OA of the hand. Here, we provided all related information about these variants in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}.

Identification of OA Risk Genes {#s2_2}
-------------------------------

For each of these 187 genetic variants, if this variant is an intronic variant, we select its corresponding gene. If this variant is an intergenic variant, we select its corresponding nearest upstream and downstream genes. The gene set consists of 202 risk genes using all these 187 genetic variants, as provided in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}.

Function Analysis {#s2_3}
-----------------

We used the HaploReg tool (v4.1) to annotate these 187 genetic variants and evaluate how many genetic variants are coding and noncoding mutations ([@B34]; [@B35]). The reference information is from the 1000 Genomes Project ([@B34]; [@B35]).

eQTLs Analysis {#s2_4}
--------------

When noncoding genetic variants are identified, we conducted an eQTLs analysis to evaluate the effect of these genetic variants on gene expression using Phenol Scanner (v2), a database of human genotype--phenotype associations ([@B29]; [@B11]).

Identification of OA Risk Pathways {#s2_5}
----------------------------------

Here, we selected the pathway resources from KEGG and GO databases, as provided in Web-based Gene Set Analysis Toolkit (WebGestalt version 2019) ([@B36]). To identify a potential OA risk pathway, the hypergeometric test was used to evaluate an overrepresentation of the OA risk genes among all the genes in the selected pathway, as did in previous studies ([@B1]; [@B44]; [@B10]; [@B20]; [@B36]). For a given pathway, the *P* value of observing more than *K* OA risk genes could be calculated by
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where *N* is the total number of genes that are of interest (the reference gene list), *S* is the number of all OA risk genes (here, n = 202), *m* is the number of genes in the pathway, and *K* is the number of OA risk genes in the pathway, as did in previous studies ([@B17]; [@B16]; [@B19]; [@B24]; [@B26]; [@B38]).

Using WebGestalt version 2019, the minimum number of genes for a category is 5, and the maximum number of genes for a category is 2000. In addition, we used the BH multiple-test adjustment method to adjust the *P* value of each pathway. A specific pathway with adjusted FDR \< 0.05 is considered to be statistically significant. A specific pathway with unadjusted *P* \< 0.05 is considered to be suggestively significant.

OA Case--Control Gene Expression Analysis {#s2_6}
-----------------------------------------

We conducted an OA case--control gene expression analysis to evaluate the differential expression of these 202 risk genes, as provided in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. The gene expression profile dataset is from peripheral blood mononuclear cells of 106 OA patients and 33 sex and age-matched healthy controls, which is a subset of the Genetics osteoarthritis and Progression study ([@B25]). Here, we used the interactive web tool GEO2R to identify genes that are differentially expressed in OA patients and healthy controls. A gene with unadjusted *P* \< 0.05 is considered to be suggestively differentially expressed. In addition, we used the Bonferroni correction method to adjust these *P* values and define the statistically differential expression, as described in a previous study ([@B12]).

Results {#s3}
=======

Function Analysis {#s3_1}
-----------------

Function analysis using HaploReg tool (v4.1) showed that eight genetic variants, rs12193102, rs35611929, rs375575359, rs528981060, rs532464664, rs541612392, rs547116051, and rs547181612, were not found in 1000 Genomes Phase 1 data. In the remaining 179 genetic variants, 11 genetic variants are coding mutations, and the other 168 genetic variants are noncoding mutations. More detailed information is provided in [**Supplementary Table 2**](#SM2){ref-type="supplementary-material"}.

eQTLs Analysis {#s3_2}
--------------

Using Phenol Scanner (v2), the eQTLs analysis showed that 165 of these 187 genetic variants could significantly regulate the expression of nearby genes with *P* \< 0.01. We found that the other 22 genetic variants were not eQTLs including rs111427307, rs11335718, rs11409738, rs12028630, rs12193102, rs138063419, rs143083812, rs150198051, rs201708019, rs35087650, rs35912128, rs375575359, rs4867568, rs528981060, rs541612392, rs547116051, rs547181612, rs5834501, rs62262139, rs6557013, rs7510312, and rs9930333. More detailed information is provided in [**Supplementary Table 3**](#SM3){ref-type="supplementary-material"}.

Identification of OA-Related KEGG Pathways {#s3_3}
------------------------------------------

Using these 202 OA risk genes, we identified 29 suggestively significant KEGG pathways (unadjusted *P* \< 0.05). Here, we provide the top 20 significant pathways, as provided in [**Table 1**](#T1){ref-type="table"}. The transforming growth factor β (TGF-β) signaling pathway is the most significant signal (*P* = 5.98E−05). Importantly, this is the only pathway after the BH multiple-test adjustment with FDR = 0.02. In addition, we identified other OA risk pathways including inflammatory bowel disease (IBD), human T-cell leukemia virus 1 infection, RA, influenza A, asthma, tuberculosis, prostate cancer, hematopoietic cell lineage, transcriptional misregulation in cancer, allograft rejection, mitogen-activated protein kinase (MAPK) signaling pathway, T~H~7 cell differentiation, graft-versus-host disease, toxoplasmosis, type 1 diabetes mellitus, cell cycle, intestinal immune network for IgA production, autoimmune thyroid disease, and ubiquitin-mediated proteolysis. More detailed information is described in [**Table 1**](#T1){ref-type="table"}.

###### 

Top 20 osteoarthritis risk pathways identified in KEGG database.

  Gene set   Description                                          Size   Expect   Ratio   *P*        FDR
  ---------- ---------------------------------------------------- ------ -------- ------- ---------- ------
  hsa04350   TGF-β signaling pathway                              84     0.43     11.70   5.98E−05   0.02
  hsa05321   Inflammatory bowel disease                           65     0.33     9.07    4.27E−03   0.41
  hsa05166   Human T-cell leukemia virus 1 infection              255    1.30     3.85    8.91E−03   0.41
  hsa05323   Rheumatoid arthritis                                 90     0.46     6.55    1.05E−02   0.41
  hsa05164   Influenza A                                          171    0.87     4.60    1.07E−02   0.41
  hsa05310   Asthma                                               31     0.16     12.68   1.07E−02   0.41
  hsa05152   Tuberculosis                                         179    0.91     4.39    1.25E−02   0.41
  hsa05215   Prostate cancer                                      97     0.49     6.08    1.29E−02   0.41
  hsa04640   Hematopoietic cell lineage                           97     0.49     6.08    1.29E−02   0.41
  hsa05202   Transcriptional misregulation in cancer              186    0.95     4.23    1.42E−02   0.41
  hsa05330   Allograft rejection                                  38     0.19     10.35   1.58E−02   0.41
  hsa04010   Mitogen-activated protein kinase signaling pathway   295    1.50     3.33    1.60E−02   0.41
  hsa04659   T~H~17 cell differentiation                          107    0.54     5.51    1.68E−02   0.41
  hsa05332   Graft-versus-host disease                            41     0.21     9.59    1.82E−02   0.41
  hsa05145   Toxoplasmosis                                        113    0.57     5.22    1.94E−02   0.41
  hsa04940   Type 1 diabetes mellitus                             43     0.22     9.14    2.00E−02   0.41
  hsa04110   Cell cycle                                           124    0.63     4.76    2.47E−02   0.46
  hsa04672   Intestinal immune network for IgA production         49     0.25     8.02    2.55E−02   0.46
  hsa05320   Autoimmune thyroid disease                           53     0.27     7.42    2.95E−02   0.51
  hsa04120   Ubiquitin-mediated proteolysis                       137    0.70     4.30    3.19E−02   0.51

Identification of OA-Related GO Biological Processes {#s3_4}
----------------------------------------------------

Using these 202 OA risk genes, we identified 24 statistically significant GO biological processes (FDR \< 0.05). These biological processes could be mainly divided into two classes including differentiation and development. The differentiation-related biological processes consist of chondrocyte differentiation, regulation of chondrocyte differentiation, positive regulation of chondrocyte differentiation, regulation of epithelial cell proliferation, regulation of cell proliferation, and epithelial cell proliferation. The development-related biological processes consist of regulation of cartilage development, cartilage development, connective tissue development, chondrocyte development, skeletal system development, liver development, hepaticobiliary system development, positive regulation of cartilage development, striated muscle tissue development, and muscle tissue development. Here, we provide the top 20 significant biological processes, as provided in [**Table 2**](#T2){ref-type="table"}.

###### 

Top 20 osteoarthritis risk biological processes identified in GO database.

  Gene set     Description                                                                                       Size   Expect   Ratio    *P*        FDR
  ------------ ------------------------------------------------------------------------------------------------- ------ -------- -------- ---------- ----------
  GO:0002062   Chondrocyte differentiation                                                                       119    0.7497   12.004   6.01E−08   5.00E−04
  GO:0061035   Regulation of cartilage development                                                               65     0.4095   17.093   1.66E−07   8.00E−04
  GO:0032330   Regulation of chondrocyte differentiation                                                         47     0.2961   20.263   4.71E−07   1.40E−03
  GO:0051216   Cartilage development                                                                             205    1.2916   7.7426   6.65E−07   1.50E−03
  GO:0061448   Connective tissue development                                                                     265    1.6696   6.5885   8.89E−07   1.60E−03
  GO:0032332   Positive regulation of chondrocyte differentiation                                                20     0.126    31.745   6.67E−06   1.01E−02
  GO:0002063   Chondrocyte development                                                                           46     0.2898   17.253   0          1.31E−02
  GO:0001501   Skeletal system development                                                                       506    3.1879   4.0779   0          1.98E−02
  GO:0001503   Ossification                                                                                      371    2.3374   4.7061   0          2.21E−02
  GO:0001889   Liver development                                                                                 137    0.8631   8.11     0          2.21E−02
  GO:0070848   Response to growth factor                                                                         690    4.3472   3.4505   0          2.21E−02
  GO:0061008   Hepaticobiliary system development                                                                140    0.882    7.9362   0          2.21E−02
  GO:0050678   Regulation of epithelial cell proliferation                                                       318    2.0035   4.9913   0          2.25E−02
  GO:0009887   Animal organ morphogenesis                                                                        974    6.1364   2.9333   0          2.25E−02
  GO:0061036   Positive regulation of cartilage development                                                      31     0.1953   20.48    0          2.40E−02
  GO:0090100   Positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway   101    0.6363   9.4291   0          2.40E−02
  GO:0060389   Pathway-restricted SMAD protein phosphorylation                                                   64     0.4032   12.4     1.00E−04   2.74E−02
  GO:0014706   Striated muscle tissue development                                                                357    2.2492   4.446    1.00E−04   4.10E−02
  GO:0090092   Regulation of transmembrane receptor protein serine/threonine kinase signaling pathway            224    1.4113   5.6687   1.00E−04   4.10E−02
  GO:0042127   Regulation of cell proliferation                                                                  1564   9.8536   2.3342   1.00E−04   4.13E−02

Identification of OA-Related GO Molecular Functions {#s3_5}
---------------------------------------------------

Using these 202 OA risk genes, we identified only one statistically significant GO molecular function (FDR \< 0.05) TGF-β receptor binding (*P* = 9.30E−06). Here, we provide the top 20 significant molecular functions, as provided in [**Table 3**](#T3){ref-type="table"}. Most of these molecular functions are related with binding including TGF-β receptor binding, phospholipid binding, TGF-β binding, peptide antigen binding, antigen binding, phosphatase binding, type II TGF-β receptor binding, protein phosphatase binding, lipid binding, bridging protein binding, apolipoprotein binding, cytokine receptor binding, and cytokine binding.

###### 

Top 20 osteoarthritis risk molecular functions identified in GO database.

  Gene set     Description                                                                Size   Expect   Ratio   *P*        FDR
  ------------ -------------------------------------------------------------------------- ------ -------- ------- ---------- ------
  GO:0005160   Transforming growth factor β receptor binding                              51     0.28     17.57   9.30E−06   0.02
  GO:0005543   Phospholipid binding                                                       412    2.30     4.35    1.00E−04   0.09
  GO:0050431   Transforming growth factor β binding                                       22     0.12     24.44   2.00E−04   0.09
  GO:0042605   Peptide antigen binding                                                    22     0.12     24.44   2.00E−04   0.09
  GO:0003823   Antigen binding                                                            55     0.31     13.04   2.00E−04   0.09
  GO:0008083   Growth factor activity                                                     163    0.91     6.60    3.00E−04   0.09
  GO:0019902   Phosphatase binding                                                        178    0.99     6.04    5.00E−04   0.13
  GO:0005114   Type II transforming growth factor β receptor binding                      7      0.04     51.22   6.00E−04   0.15
  GO:0019903   Protein phosphatase binding                                                133    0.74     6.74    9.00E−04   0.19
  GO:0003777   Microtubule motor activity                                                 83     0.46     8.64    1.20E−03   0.22
  GO:0005201   Extracellular matrix structural constituent                                158    0.88     5.67    1.90E−03   0.33
  GO:0008289   Lipid binding                                                              718    4.01     2.75    2.10E−03   0.34
  GO:0030674   Protein binding, bridging                                                  172    0.96     5.21    2.80E−03   0.39
  GO:0034185   Apolipoprotein binding                                                     15     0.08     23.90   3.10E−03   0.39
  GO:0005024   Transforming growth factor β--activated receptor activity                  15     0.08     23.90   3.10E−03   0.39
  GO:0001228   DNA-binding transcription activator activity, RNA polymerase II specific   444    2.48     3.23    3.40E−03   0.39
  GO:0004675   Transmembrane receptor protein serine/threonine kinase activity            17     0.09     21.09   4.00E−03   0.44
  GO:0005126   Cytokine receptor binding                                                  274    1.53     3.93    4.30E−03   0.45
  GO:0060090   Molecular adaptor activity                                                 194    1.08     4.62    4.60E−03   0.46
  GO:0019955   Cytokine binding                                                           127    0.71     5.65    5.60E−03   0.52

Identification of OA-Related GO Cellular Components {#s3_6}
---------------------------------------------------

Using these 202 OA risk genes, we identified five statistically significant GO cellular components (FDR \< 0.05) including extracellular matrix, COPII-coated endoplasmic reticulum (ER) to Golgi transport vesicle, collagen-containing extracellular matrix, extracellular matrix component, and major histocompatibility complex (MHC) protein. In addition, the top 20 significant cellular components also include coated vesicle, nucleoplasm part, endocytic vesicle membrane, fibrillar collagen trimer, banded collagen fibril, Golgi-associated vesicle, MHC class II protein complex, ER to Golgi transport vesicle membrane, cytoplasmic vesicle membrane, ER lumen, vesicle membrane, complex of collagen trimers, ER part, microtubule associated complex, and sarcoplasm. More detailed information is described in [**Table 4**](#T4){ref-type="table"}.

###### 

Top 20 osteoarthritis risk cellular components identified in GO database.

  Gene set     Description                                                          Size   Expect   Ratio   *P*        FDR
  ------------ -------------------------------------------------------------------- ------ -------- ------- ---------- ------
  GO:0031012   Extracellular matrix                                                 496    2.37     4.65    0          0.02
  GO:0030134   COPII-coated endoplasmic reticulum (ER) to Golgi transport vesicle   87     0.42     12.04   1.00E−04   0.02
  GO:0062023   Collagen-containing extracellular matrix                             366    1.75     5.15    1.00E−04   0.02
  GO:0044420   Extracellular matrix component                                       49     0.23     17.10   1.00E−04   0.03
  GO:0042611   Major histocompatibility complex (MHC) protein complex               21     0.10     29.93   1.00E−04   0.03
  GO:0030135   Coated vesicle                                                       275    1.31     5.33    3.00E−04   0.07
  GO:0044451   Nucleoplasm part                                                     1087   5.19     2.70    6.00E−04   0.10
  GO:0030666   Endocytic vesicle membrane                                           160    0.76     6.55    1.00E−03   0.14
  GO:0005583   Fibrillar collagen trimer                                            11     0.05     38.09   1.20E−03   0.14
  GO:0098643   Banded collagen fibril                                               11     0.05     38.09   1.20E−03   0.14
  GO:0005798   Golgi-associated vesicle                                             169    0.81     6.20    1.30E−03   0.14
  GO:0042613   MHC class II protein complex                                         15     0.07     27.93   2.30E−03   0.22
  GO:0012507   ER to Golgi transport vesicle membrane                               57     0.27     11.03   2.60E−03   0.23
  GO:0030659   Cytoplasmic vesicle membrane                                         746    3.56     2.81    2.90E−03   0.24
  GO:0005788   Endoplasmic reticulum lumen                                          306    1.46     4.11    3.40E−03   0.25
  GO:0012506   Vesicle membrane                                                     767    3.66     2.73    3.50E−03   0.25
  GO:0098644   Complex of collagen trimers                                          19     0.09     22.05   3.70E−03   0.25
  GO:0044432   Endoplasmic reticulum part                                           1332   6.36     2.20    4.00E−03   0.26
  GO:0005875   Microtubule associated complex                                       148    0.71     5.66    5.50E−03   0.34
  GO:0016528   Sarcoplasm                                                           77     0.37     8.16    6.00E−03   0.34

OA Case--Control Gene Expression Analysis {#s3_7}
-----------------------------------------

Of the selected 202 risk genes, 122 risk genes were included in the OA case--control gene expression dataset, as provided in [**Supplementary Table 4**](#SM4){ref-type="supplementary-material"}. The results showed that 44 of these 122 risk genes showed suggestively differential expression in OA cases compared with controls (*P* \< 0.05). Importantly, three genes including WWP2, COG5, and MAPT showed statistically different expression in OA cases compared with controls (*P* \< 0.05/122 = 4.10E−04), as described in [**Table 5**](#T5){ref-type="table"}.

###### 

Forty-four significantly differentially expressed osteoarthritis risk genes.

  ID             *T*          *B*        Fold change   Gene        *P*
  -------------- ------------ ---------- ------------- ----------- ----------
  ILMN_1659703   −4.6029458   3.22309    0.87          WWP2        9.31E−06
  ILMN_1721535   4.0329713    1.10042    1.26          COG5        9.05E−05
  ILMN_1800049   −3.68066     −0.10141   0.96          MAPT        3.32E−04
  ILMN_1804895   −3.4402192   −0.86996   0.92          LSMEM1      7.68E−04
  ILMN_1778886   −3.397218    −1.00284   0.92          ZNF345      8.89E−04
  ILMN_1738239   −3.3661954   −1.09784   0.84          RBM6        9.86E−04
  ILMN_1698621   3.1752911    −1.66604   1.07          COG5        1.84E−03
  ILMN_1768261   −3.0820359   −1.93322   0.95          PRDM2       2.48E−03
  ILMN_1673708   2.9367424    −2.33566   1.02          HDAC9       3.88E−03
  ILMN_1776858   −2.924587    −2.36856   0.93          DUS4L       4.03E−03
  ILMN_1772218   2.8667893    −2.52332   1.12          HLA-DPA1    4.79E−03
  ILMN_1785402   −2.7406448   −2.85157   0.95          LTBP1       6.94E−03
  ILMN_1790384   −2.7296251   −2.87962   0.96          PRDM2       7.16E−03
  ILMN_1802973   −2.7280423   −2.88364   0.87          ANAPC4      7.20E−03
  ILMN_1699469   2.6997749    −2.95509   1.03          KCNIP4      7.80E−03
  ILMN_1749026   −2.6961724   −2.96415   0.98          LCT         7.88E−03
  ILMN_1693559   2.678254     −3.00904   1.02          DOT1L       8.29E−03
  ILMN_1690442   −2.6764894   −3.01345   0.97          TMEM241     8.34E−03
  ILMN_2381121   2.6586005    −3.05797   1.06          UQCC1       8.77E−03
  ILMN_1682981   −2.6104688   −3.17642   0.95          SMG6        1.00E−02
  ILMN_1753353   2.5464314    −3.33099   1.07          SLBP        1.20E−02
  ILMN_1823056   −2.4053844   −3.65907   0.98          CCDC33      1.75E−02
  ILMN_1716651   2.4049149    −3.66013   1.07          RUNX2       1.75E−02
  ILMN_2408885   2.3961067    −3.68005   1.03          HDAC9       1.79E−02
  ILMN_1701361   −2.3821458   −3.71148   0.98          LURAP1L     1.86E−02
  ILMN_1754121   2.3523213    −3.77806   1.09          CSK         2.01E−02
  ILMN_1693427   −2.3253143   −3.83768   0.98          GLIS3       2.15E−02
  ILMN_1747386   −2.3074266   −3.87682   0.98          GLIS3       2.25E−02
  ILMN_1717780   2.2917001    −3.911     1.02          PLEC        2.34E−02
  ILMN_1771987   2.2874158    −3.92028   1.12          SLC44A2     2.37E−02
  ILMN_2145670   2.2761251    −3.94464   1.03          TNC         2.44E−02
  ILMN_1784287   2.2239902    −4.05569   1.17          TGFBR3      2.78E−02
  ILMN_2129668   −2.200499    −4.10495   0.98          TGFB1       2.94E−02
  ILMN_1780291   −2.1782335   −4.15119   0.95          NFAT5       3.11E−02
  ILMN_1882354   2.1649163    −4.17863   1.15          FAM53A      3.21E−02
  ILMN_1680399   −2.1603694   −4.18797   0.97          KAZN        3.25E−02
  ILMN_1726387   −2.1502554   −4.20866   0.97          NF1         3.33E−02
  ILMN_1654421   −2.129798    −4.25025   0.94          MPHOSPH9    3.50E−02
  ILMN_1724734   2.1181634    −4.27374   1.03          UQCC1       3.59E−02
  ILMN_2381559   2.0754774    −4.35887   1.02          ASTN2       3.98E−02
  ILMN_1673620   −2.0711976   −4.36732   0.97          KIF26B      4.02E−02
  ILMN_1871893   −2.0480746   −4.41267   0.98          LINC01507   4.24E−02
  ILMN_2046073   2.0412532    −4.42596   1.02          LCT         4.31E−02
  ILMN_1813277   2.0065873    −4.49284   1.11          SUPT3H      4.67E−02

T, Moderated t-statistic; B, B-statistic or log-odds that the gene is differentially expressed; F, Moderated F-statistic combines the t-statistics for all the pair-wise comparisons into an overall test of significance for that gene.

Discussion {#s4}
==========

In this study, we first selected 187 independent genetic variants identified by GWAS (*P* \< 1.00E−05) and found that most of these genetic variants are noncoding mutations. We then conducted an eQTLs analysis and found that 165 of these 187 genetic variants could significantly regulate the expression of nearby genes. Third, we identified OA susceptibility genes corresponding to these genetic variants, conducted a pathway analysis, and identified novel OA-related KEGG pathways, GO biological processes, GO molecular functions, and GO cellular components.

In KEGG database, TGF-β signaling pathway is the most significant signal (*P* = 5.98E−05) and is the only pathway after the BH multiple-test adjustment with FDR = 0.02. Our finding is consistent with previous findings. Recent findings provide substantial evidence that TGF-β signaling contributes to OA development and progression ([@B27]; [@B7]). In addition, we found the association of OA with other human diseases including IBD, RA, asthma, prostate cancer, hematopoietic cell lineage, transcriptional misregulation in cancer, allograft rejection, MAPK signaling pathway, graft-versus-host disease, type 1 diabetes mellitus, and autoimmune thyroid disease. Previous study supported our finding about the association of human T-cell leukemia virus 1 infection pathway with OA. It is reported that human T lymphotropic virus type I retrovirus infection could alter the expression of inflammatory cytokines in primary OA ([@B40]). Here, we highlighted the association of T~H~17 cell differentiation pathway with OA. Evidence showed that complement could drive T~H~17 cell differentiation and trigger autoimmune arthritis ([@B9]; [@B15]).

In GO database, we identified 24 statistically significant GO biological processes, one statistically significant GO molecular function, and five statistically significant GO cellular components (FDR \< 0.05). These signals are related with chondrocyte differentiation and development, which are all known biological pathways associated with OA. Take the chondrocyte differentiation (GO:0002062), for example, previous studies also supported the hypertrophic differentiation of chondrocytes in OA ([@B4]; [@B8]). Some biological pathways are related with TGF-β signaling binding, such as TGF-β receptor binding, TGF-β binding, and type II TGF-β receptor binding. The phospholipid binding (GO:0005543) is the second significant signal among the top 20 OA risk molecular functions identified in GO database. Evidence shows that lipids are important nutrients in chondrocyte metabolism ([@B33]). The lipid availability is important to keep cartilage status and OA development ([@B33]).

Using an OA case--control gene expression analysis, we showed that 44 of these 122 risk genes were suggestively differentially expressed in OA cases compared with controls (*P* \< 0.05). Three genes, WWP2, COG5, and MAPT, were statistically differentially expressed in OA cases compared with controls (*P* \< 0.05/122 = 4.10E−04).

In summary, we believe that these findings provide further insight into the underlying genetic mechanisms for these newly identified OA risk genes. Although these are interesting findings, we also realize some limitations to our study. Until now, pathway analyses of RA GWAS datasets have widely been reported, but not OA GWAS datasets ([@B6]; [@B5]; [@B14]; [@B28]; [@B43]). In the future, we will compare our findings using top OA genetic variants with pathway analysis of OA using the whole GWAS datasets and further clarify the differences between top OA genetic variants and the whole OA GWAS datasets. In addition, a gene expression analysis in OA-related tissues is necessary to demonstrate that these pathways are deregulated in OA cases and controls. However, this kind of gene expression datasets in OA-related tissues is not available now. Hence, we will further evaluate our findings using gene expression datasets in OA-related tissues in the future.
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